Abstracts tagged "Angiotensin"

Abstract Number: 1146 • 2018 ACR/ARHP Annual Meeting
The Association of Raas Inhibitor Use with Osteoporosis. Findings from the Women’s Health Initiative
Laura Carbone¹, Sowmya Vassan², Ross Prentice², Greg Harshfield¹, Bernhard Haring³, Jane A. Cauley⁴ and Karen Johnson⁵, ¹Medical College of Georgia at Augusta University, Augusta, GA, ²Fred Hutchinson Cancer Research Center, Seattle, WA, ³University of Wurzburg, Bavaria, Germany, ⁴University of Pittsburgh, PIttsburgh, PA, ⁵University of TN Health Science Center, Memphis, TN
Background/Purpose: Experimental studies have implicated a role for the Renin Angiotensin Aldosterone System (RAAS) in osteoporosis. However, the relationship of pharmacological inhibition of the RAAS…
Abstract Number: 468 • 2016 ACR/ARHP Annual Meeting
Angiotensin II Exacerbates Bone Destruction in TNF-Transgenic Arthritis Mice
Takafumi Mito¹, Tomoyuki Mukai², Shunichi Fujita², Akiko Nagasu², Hiroyasu Hirano², Teruki Sone³ and Yoshitaka Morita², ¹rheumatology, Kawasaki medical school, Okayama, Japan, ²Rheumatology, Kawasaki medical school, Okayama, Japan, ³Nuclear Medicine, Kawasaki medical school, Okayama, Japan
Background/Purpose: Angiotensin II (Ang II) is known to function on various organs including kidneys, adrenal glands as well as the nervous and cardiovascular systems. In…
Abstract Number: 1712 • 2014 ACR/ARHP Annual Meeting
Monocytic Angiotensin and Endothelin Receptor Imbalance Determines Secretion of the Profibrotic Chemokine Ligand CCL18
Judith Rademacher¹, Jeannine Guenther², Angela Kill³, Elise Siegert⁴ and Gabriela Riemekasten⁵, ¹Charité University Hospital and German Rheumatism Research Centre, a Leibniz Institute, Berlin, Germany, 10117 Berlin, Germany, ²Rheumatology/Clinical Immunology, Charité University Hospital and German Rheumatism Research Centre, a Leibniz Institute, Berlin, Germany, Berlin, Germany, ³Rheumatology and clinical Immunology, Charité University Hospital, German Rheumatology Research Center, a Leibniz Institute, Berlin, Germany, ⁴Rheumatology and Clinical Immunology, Charité – University Hospital, Berlin, Germany, ⁵Charité University Hospital and German Rheumatism Research Centre, a Leibniz Institute, Berlin, Germany
Background/Purpose Circulating monocytes are progrenitor of extra-cellular matrix producing cells involved in fibrosis and show highest expression of angiotensin II (ATR) and endothelin receptors (ETR)…
Abstract Number: 2230 • 2013 ACR/ARHP Annual Meeting
Specific Angiotensin Type II Receptor Stimulation Attenuates Collagen-Induced Arthritis Via Enhancement Of FoxP3 Regulatory T Cells
Bettina Sehnert¹, Veronica Valero-Esquitino², Georg Schett³, Ulrika Muscha Steckelings² and Reinhard E. Voll⁴, ¹Rheumatology and Clinical Immunology & Centre of Chronic Immunodeficiency,, University Hospital Freiburg, Freiburg, Germany, ²Center for Cardiovascular Research, Medical Faculty Berlin, Berlin, Germany, ³Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁴Rheumatology and Clinical Immunology & Centre of Chronic Immunodeficiency, University Hospital Freiburg, Freiburg, Germany
Background/Purpose: The renin-angiotensin system (RAS) is known to play an important role in inflammation, fibrosis, and end-organ damage. Moreover, AT2R signalling exerts anti-inflammatory and anti-apoptotic…
Abstract Number: 1491 • 2012 ACR/ARHP Annual Meeting
Systemic Sclerosis – Effects of Agonistic Autoantibodies Directed Against the Angiotensin Receptor Type 1 and the Endothelin Receptor Type A On Effector Cells
Jeannine Guenther¹, Angela Kill², Mike O. Becker³ and Gabriela Riemekasten⁴, ¹Rheumatology/Clinical Immunology, Charité University Hospital and German Rheumatism Research Centre, a Leibniz Institute, Berlin, Germany, Berlin, Germany, ²Rheumatology and clinical Immunology, Charité University Hospital and German Rheumatism Research Centre, a Leibniz Institute, Berlin, Germany, ³Rheumatology and Clinical Immunology, Charité University Hospital, Berlin, Germany, ⁴Charité University Hospital and German Rheumatism Research Centre, a Leibniz Institute, Berlin, Germany
Background/Purpose: Autoimmunity, vasculopathy and fibrosis are features of systemic sclerosis (SSc). The functional link between these three pathophysiological components is still missing. Research suggests an…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].